π¬Deep Research
ELDN β Eledon Pharmaceuticals Inc Β· catalysts, narrative & risks
Eleon Pharmaceuticals, Inc. (Nasdaq: ELDN) β Company Context
Eleon is a clinical-stage biotechnology company headquartered in Irvine, California, developing immune-modulating therapies. Its lead investigational product is tegoprubart, an anti-CD40L antibody, targeting organ transplant rejection (kidney, liver, islet cell, xenotransplantation) and ALS [1], [2], [19]. The company is not yet profitable [18]. The prior-calendar event of an earnings release on 2026-11-13 is largely corroborated by the new sources below, with one caveat noted later.
Key Recent Catalysts (roughly JulyβOctober 2026)
AI-assisted research from the K3vl4r desk β not personalized investment advice. More research β